QC
TEVA icon

Quent Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Quent Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-500
Closed -$5.1K – 1351
2023
Q3 		$5.1K Hold
500
– – ﹤0.01% 1046
2023
Q2 		$3.77K Hold
500
– – ﹤0.01% 1095
2023
Q1 		$4.42K Hold
500
– – ﹤0.01% 1063
2022
Q4 		$4.56K Hold
500
– – ﹤0.01% 1027
2022
Q3 		$4K Hold
500
– – ﹤0.01% 1018
2022
Q2 		$4K Sell
500
-166
-25% -$1.45K ﹤0.01% 995
2022
Q1 		$6K Hold
666
– – ﹤0.01% 1020
2021
Q4 		$5K Buy
+666
New +$6.01K ﹤0.01% 931

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Quent Capital's TEVA Position: Q4 2023 in Review

Quent Capital sold out of Teva Pharmaceuticals (TEVA) in Q4 2023, closing a stake of 500 shares — an estimated $5.1K sold.

Quent Capital first reported a position in TEVA in Q4 2021 and held it in 8 quarters. The position peaked at $6K in Q1 2022. 447 funds tracked by Wall St. Rank hold TEVA as of Q4 2023.

  • Quent Capital reported no remaining Teva Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Quent Capital sold 500 Teva Pharmaceuticals shares in Q4 2023, an estimated $5.1K.
  • Quent Capital first reported a position in Teva Pharmaceuticals in Q4 2021 and held it in 8 quarters.
  • Quent Capital's Teva Pharmaceuticals position peaked at $6K in Q1 2022.
  • 447 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2023.

Based on Quent Capital's 13F filing for Q4 2023, filed 19 Jan 2024.